Mother Who Lost Infant Son to Medical Error to Join Panel at World Patient Safety, Science & Technology Summit
New mother Deahna Visscher was feeling hopeful. Although her son Grant had been born with a heart defect, he was doing very well after surgery. Just 11-days old, doctors felt he could soon leave the hospital. But that didn’t happen. A nurse incorrectly inserted a feeding tube piercing the little infant’s trachea and filling his lungs with fluid. “The nurse asked me to go out into the hall and ask for help,” recalls Deahna. “I told them my son was turning blue and I watched as 20 staff members tried to resuscitate him. “ Grant was pronounced dead at 9:10 p.m.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005694/en/
Deahna Visscher will share her personal experience of losing her 11-day old son to a medical error. (Photo: Business Wire)
Since that tragic night in 2008, Deahna Visscher has become a fierce patient advocate. The Patient Safety Movement Foundation (PSMF) is happy to announce her participation in a compelling panel on Nasogastric Feeding and Draining Tube Placement and Verification at the 6th Annual World Patient Safety, Science & Technology Summit on Saturday, February 24, 2018. Feeding and draining tubes are used routinely in hospitals and a recent study showed that 59% of nasogastric feeding tubes are misplaced in newborn children less than four weeks old, causing serious harm and in some cases death.1
Since Grant’s tragic death, Children’s Hospital Colorado has crafted procedures to ensure that such errors are not repeated. Their procedures and those of a multi-disciplinary experts were utilized in creating a new “Actionable Patient Safety Solutions” (APSS) developed by the PSMF which will be released publicly during the summit.
What is Nasogastric Feeding and Draining Tube Placement and Verification and why is it critical to patient safety? Nasogastric tubes (NGTs) are a commonly used in clinical practice for decompression or for administering nutrition, fluids and medications.
Studies of adult patients report NGT misplacement with serious harm to patients in 1.3 to 3.2% of tube placements (Gilbertson 2011, Bourgault 2009). A 2009 study of tube placements in neonates (infants less than four weeks old) showed that 59% of NGTs are misplaced the majority of these in the esophagus (October 2009).
The 6th Annual World Patient Safety panelists are:
Moderator Frances Healey , PhD, RN, Deputy Director of Patient Safety, National Health Service Improvement – Dr. Healey’s role includes leading the National Patient Safety Alerting System and clinical review teams of all nationally reported death and severe harm incidents.
- Beth Lyman, MSN, RN, CNSC , Senior Program Coordinator, Children’s Mercy Kansas City - Ms. Lyman is a member of the board of directors of the American Society of Parenteral and Enteral Nutrition. She worked with the board to develop the New Opportunities for Verification of Enteral tube Location (NOVEL) project which is an inter-organization, inter-disciplinary and international effort to promote best practice for NG tube placement verification.
- Deahna Visscher , Patient Advocate – Since the death of her son in 2008, Ms. Visscher has been on a mission to prevent further deaths from misplaced feeding tubes. She sits on the Patient Safety and Reliability Committee at Children’s Hospital Colorado and the New Opportunities for Verification of Enteral tube Location (NOVEL) project.
- Christine Peyton , RN, Clinical Nurse Specialist, Children’s Hospital Colorado – Ms. Peyton promotes, develops and implements evidence-based best practices for pediatric nursing. She’s a clinical expert on revision and development of policies and guidelines for pediatric cardiology and critical care.
- David Kershenobich , MD, Director General, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran – Former member of the Board of Governors of the National University of Mexico (UNAM) (2005-2012), Dr. Kershenobich served as Mexico’s Surgeon General from October 2011 to June 2012 and is Past President of the International Association for the Study of the Liver and the National Academy of Medicine of Mexico. He is an Honorary Fellow of the Royal College of Physicians, England.
For more information, please visit the Patient Safety Movement Foundation website. Members of the media may request a press pass by visiting http://bit.ly/2mCeyay or by contacting Tanya Lyon – phone (949) 351-2858 or email email@example.com.
1 AM Bourgault, MA Halm. Feeding tube placement in adults: safe verification method for blindly inserted tubes.. Am J Crit Care 18, 73-6 (2009).
About Patient Safety Movement Foundation:
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.
Patient Safety Movement Foundation
Tanya Lyon, 949-351-2858
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Universal Laser Systems Expands Its Materials Database with Henkel, Hexcel and Saint-Gobain Materials19.6.2018 12:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of Henkel, Hexcel® and Saint-Gobain materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The Henkel, Hexcel and Saint-Gobain materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: Henkel Bergquist™ Gap Pad® VO Thermal Material Henkel Bergquist™ Hi-Flow® 105 Thermal Material Henkel LOCTITE® EA 7000 AERO Film Henkel Hysol® EA 9696 AERO Film Henkel Bergquist™ Sil-Pad A2000 Thermal Material Hexcel® HexForce® 353 Aramid Fabric Hexcel® HexForce® 282 Carbon Fabric Saint-Gobain CHEMFILM® DF100 Cast PTFE Film Saint-Gobain CHEMFILM® ETFE-E2 Extruded Fluoropolymer Film Laser processing notes, describing the results of the laser-material interaction fo
Valence Advises Itaúsa on Sale of Brazilian Chemical Co Elekeiroz to H.I.G. Capital19.6.2018 11:57 | Pressemelding
The Valence Group acted as advisor to Itaúsa on its sale of Brazilian chemical company Elekeiroz for R$160 million (EV), reduced by the net debt and proportionate to its shareholding (96.5% of total capital stock). The Company is a leading local producer of oxo-alcohols, plasticizers and anhydrides. About Itaúsa Itaúsa is a Brazilian holding company which controls several companies active in areas such as the financial sector; industries include wood panels, bathroom fittings and fixtures; infra-structure; and retail. It is one of the largest private conglomerates in Brazil and one of the largest in the world. About Elekeiroz Founded in 1894 and headquartered in Várzea Paulista – São Paulo, Elekeiroz operates in the chemicals manufacturing market. Through two production sites in Várzea Paulista and Camaçari – Bahia, the Company’s portfolio includes Oxo-Alcohols, Plasticizers, Phthalic & Maleic Anhydrides, Sulfuric Acid and other by-products. Elekeiroz has a diversified client base, com
Dole Adds Industry Veteran Michael Solomon as President of Dole Fresh Vegetables19.6.2018 10:00 | Pressemelding
Dole Food Company, Inc. announced the appointment of Michael H. Solomon as the new President of Dole Fresh Vegetables effective June 18, 2018. As Dole Fresh Vegetables President, Solomon will have responsibility for all of the division's operations across North America. He will report directly to Dole Food Company President and Chief Executive Officer Johan Linden. With 30 years experience, including within the food and beverage industry, Solomon has a proven success record of taking high-performance brands to the next level, increasing performance and margins in sales, plant operations, and profit growth. Among other positions, Solomon has held roles of President of POM Wonderful and President and CEO of Ready Pac Foods, Inc., prior to joining Dole. “Michael has built an impressive track record of strategic, operational and commercial accomplishments,” said Johan Linden, President and Chief Executive Officer of Dole Food Company. “He has considerable experience and knowledge of the fr
IDEMIA Selected to Deliver Its Next Generation Fingerprint Matcher Engine as Part of the UK Home Office Biometrics Programme19.6.2018 07:54 | Pressemelding
This award will result in the deployment of the very latest IDEMIA fingerprint matching platform, which will deliver significant productivity improvements by offering increased accuracy fingerprint services to the stakeholders and users of the HOB Programme. In the first phase of the project IDEMIA’s solution will be deployed for use by United Kingdom National Law Enforcement agencies, to be closely followed by Immigration and Border stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005576/en/ (Photo: IDEMIA) IDEMIA’s solution is based upon its MBSS Search Platform1 with additional Services. MBSS is a flagship product of IDEMIA, combining very high scalability (over 1 billion identities possible), very high availability – designed for mission-critical systems – and integrating IDEMIA’S world-leading biometric algorithms. The IDEMIA award results from a competitive procurement. Initially a five year contract,
Vincent Fournier Joins Binary Tree as Chief Innovation Officer19.6.2018 07:00 | Pressemelding
Binary Tree has named Vincent Fournier as its first chief innovation officer, reporting to CEO Nick Wilkinson. In this critical executive management role, Vincent will lead a fast-paced, innovative, and collaborative team that helps power digital transformation. His team will develop new products and services to meet the urgent and pervasive needs of customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005126/en/ Vincent Fournier, Chief Innovation Officer at Binary Tree. (Photo: Business Wire) “The appointment of Vincent to this important new role is a key part of our strategy to define and accelerate the next phase of growth for Binary Tree and continue to drive our competitive advantage,” said Binary Tree CEO Nick Wilkinson. “We have a clear strategy, focused on transformation, innovation and the evolution of Binary Tree within the broader Microsoft ecosystem.” “I am thrilled to be joining Binary Tree during suc
Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe19.6.2018 06:00 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson presented for the first time in Europe data from pivotal Phase 3 clinical studies of the investigational compound esketamine nasal spray in treatment-resistant depression.1,2,3,4 The studies, conducted by Janssen Research & Development, LLC, were presented at the 31st International College of Neuropsychopharmacology (CINP) congress in Vienna, Austria. Data discussed from the Phase 3 programme included results from the maintenance phase of a long-term relapse prevention study in adults with treatment-resistant depression. The data found that continuing treatment with esketamine nasal spray plus an oral antidepressant in patients beyond 16 weeks showed clinically meaningful and statistically significant superiority to treatment with an oral antidepressant plus placebo nasal spray in delaying time to relapse of symptoms of depression. Furthermore, the data indicated that patients in stable remission treated with esketamine nasal sp